• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues - Product Image

The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues

  • Published: March 2010
  • 165 Pages
  • GBI Research

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Galderma S.A
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • L’Oreal
  • MORE

“The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues” provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the dermatology therapeutics market from 2001 to 2009, forecast forward to 2016

- Analysis of the leading therapeutic segments. These include Acne, Psoriasis, Dermatitis, Rosacea and Skin diseases.

- Analysis READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Global Dermatology Therapeutics Market: Scope of Research
2.1 Introduction
2.2 GBI Research Report Guidance

3 Global Dermatology Therapeutics Market: Market Characterization
3.1 Market Forecasts
3.2 Usage Patterns
3.2.1 Diseased Population
3.2.2 Treatment Seeking Population
3.2.3 Diagnosis Population
3.2.4 Prescription Population
3.2.5 Therapy Usage Patterns
3.2.6 Geographical Distribution

4 Global Dermatology Therapeutics Market: US Market
4.1 Market Overview
4.2 Market Forecasts
4.3 Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.3.5 Therapy Usage Patterns

5 Global Dermatology Therapeutics Market: European Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Usage Patterns
5.3.1 Diseased Population
5.3.2 Treatment Seeking Population
5.3.3 Diagnosis Population
5.3.4 Prescription Population
5.3.5 Therapy Usage Patterns

6 Global Dermatology Therapeutics Market : Japan Market
6.1 Market Overview
6.2 Market Forecasts
6.3 Usage Patterns
6.3.1 Diseased Population
6.3.2 Treatment Seeking Population
6.3.3 Diagnosis Population
6.3.4 Prescription Population
6.3.5 Therapy Usage Patterns

7 Global Psoriasis Therapeutics Market
7.1 Market Overview
7.2 Market Forecasts
7.3 Average Cost of Therapy
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Therapy Usage Patterns
7.5 Product Analysis
7.5.1 Enbrel (etanercept)
7.5.2 Humira (adalimumab)
7.5.3 Amevive (alefacept)
7.5.4 Remicade (infliximab)
7.5.5 Stelara (ustekinumab, CNTO1275)
7.5.6 Clobex (clobetasol propionate)
7.5.7 Tazorac (tazarotene, Avage)
7.5.8 Dovonex (calcipotriene)
7.5.9 Neoral (cyclosporine)
7.6 Drug Pipeline Analysis
7.6.1 Psoriasis Therapeutics – Phase III Clinical Pipeline
7.6.2 Psoriasis Therapeutics – Phase II Clinical Pipeline

8 Global Atopic Dermatitis Therapeutics Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Average Cost of Therapy
8.4 Usage Patterns
8.4.1 Diseased Population
8.4.2 Treatment Seeking Population
8.4.3 Diagnosis Population
8.4.4 Prescription Population
8.4.5 Therapy Usage Patterns
8.5 Product Analysis
8.5.1 Protopic (Tacrolimus)
8.5.2 Elidel (Pimecrolimus)
8.5.3 MimyX
8.5.4 Atopiclair
8.5.5 Topical Corticosteroids
8.6 Drug Pipeline Analysis

9 Global Acne Therapeutics Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Usage Patterns
9.3.1 Diseased Population
9.3.2 Treatment Seeking Population
9.3.3 Diagnosis Population
9.3.4 Prescription Population
9.3.5 Therapy Usage Patterns
9.4 Product Analysis
9.5 Drug Pipeline Analysis

10 Global Rosacea Disease Therapeutics Market
10.1 Market Overview
10.2 Market Forecasts
10.3 Average Cost of Therapy
10.4 Usage Patterns
10.4.1 Diseased Population
10.4.2 Treatment Seeking Population
10.4.3 Diagnosis Population
10.4.4 Prescription Population
10.4.5 Therapy Usage Patterns
10.5 Product Analysis
10.6 Drug Pipeline Analysis

11 Global Dermatology Therapeutics Market: Market Drivers and Restraints
11.1 Market Drivers
11.1.1 Steady Increase in the Elderly Population
11.1.2 Stable Increase in Incidence Rates for Dermatology Diseases
11.1.3 Increase in Awareness Levels of Disease Progression and Etiology
11.2 Market Restraints
11.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers
11.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic drugs

12 Global Dermatology Therapeutics Market : Key Market Trends

13 Global Dermatology Therapeutics Market: Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Profiling
13.3.1 GlaxoSmithKline plc (GSK)
13.3.2 Johnson & Johnson
13.3.3 Bayer AG
13.3.4 Merck & Co., Inc
13.3.5 Novartis AG
13.3.6 Sanofi-Aventis
13.3.7 LEO Pharma A/S
13.3.8 F. Hoffmann-La Roche Ltd
13.3.9 L’Oreal
13.3.10 Galderma S.A
13.3.11 Nestle S.A

14 Dermatology Thereapeutics Market: Pipeline Analysis
14.1 Pipeline I
14.2 Pipeline II
14.3 Pipeline III
14.4 Promising Drugs under Clinical Development
14.4.1 Voclosporin (LX211, LUVENIQ, ISA-247)
14.4.2 ABT-874 (J-695, Briakinumab)
14.4.3 CF-101
14.4.4 Orencia (abatacept, CTLA4-Ig, BMS-188667)
14.4.5 Cimzia (CDP870 certolizumab pegol)
14.4.6 Apremilast (CC10004, ACR20)
14.4.7 INCB18424
14.4.8 PH-10
14.4.9 Hivenyl
14.4.10 TF002

15 Global Dermatology Therapeutics Market: M&A Landscape
15.1 Mergers and Acquisitions
15.1.1 Overview
15.2 Licensing Agreements
15.2.1 Overview
15.2.2 Drug Discovery & Preclinical
15.2.3 Phase I
15.2.4 Phase II
15.2.5 Phase III
15.2.6 Approved Stage

16 Global Dermatology Therapeutics Market : Appendix
16.1 Market Definitions
16.2 Abbreviations
16.3 Research Methodology
16.3.1 Coverage
16.3.2 Secondary Research
16.3.3 Primary Research
16.3.4 Forecasts
16.3.5 Expert Panel Validation
16.4 Contact Us
16.5 Disclaimer

List of Tables:

Table 1: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 2: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 3: Dermatology Therapeutics Market, Global, Diseased Population, 2001-2009
Table 4: Dermatology Therapeutics Market, Global, Diseased Population, 2009-2016
Table 5: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2001-2009
Table 6: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
Table 7: Dermatology Therapeutics Market, Global, Diagnosis Population, 2001-2009
Table 8: Dermatology Therapeutics Market, Global, Diagnosis Population, 2009-2016
Table 9: Dermatology Therapeutics Market, Global, Prescription Population, 2001-2009
Table 10: Dermatology Therapeutics Market, Global, Prescription Population, 2009-2016
Table 11: Dermatology Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 12: Dermatology Therapeutics Market, Global, Usage Patterns, 2009-2016
Table 13: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2001-2009
Table 14: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2009-2016
Table 15: Dermatology Therapeutics Market, The U.S, Diseased Population, 2001-2009
Table 16: Dermatology Therapeutics Market, The U.S, Diseased Population, 2009-2016
Table 17: Dermatology Therapeutics Market, The US, Treatment Seeking Population, 2001-2009
Table 18: Dermatology Therapeutics Market, The US, Treatment Seeking Population, 2009-2016
Table 19: Dermatology Therapeutics Market, The US, Diagnosis Population, 2001-2009
Table 20: Dermatology Therapeutics Market, The US, Diagnosis Population, 2009-2016
Table 21: Dermatology Therapeutics Market, The US, Prescription Population, 2001-2009
Table 22: Dermatology Therapeutics Market, The US, Prescription Population, 2009-2016
Table 23: Dermatology Therapeutics Market, The US, Usage Patterns, 2001-2009
Table 24: Dermatology Therapeutics Market, The US, Usage Patterns, 2009-2016
Table 25: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2001-2009
Table 26: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2009-2016
Table 27: Dermatology Therapeutics Market, Europe, Diseased Population, 2001-2009
Table 28: Dermatology Therapeutics Market, Europe, Diseased Population, 2009-2016
Table 29: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2001-2009
Table 30: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2009-2016
Table 31: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2001-2009
Table 32: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2009-2016
Table 33: Dermatology Therapeutics Market, Europe, Prescription Population, 2001-2009
Table 34: Dermatology Therapeutics Market, Europe, Prescription Population, 2009-2016
Table 35: Dermatology Therapeutics Market, Europe, Usage Patterns, 2001-2009
Table 36: Dermatology Therapeutics Market, Europe, Usage Patterns, 2009-2016
Table 37: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2001-2009
Table 38: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2009-2016
Table 39: Dermatology Therapeutics Market, Japan, Diseased Population, 2001-2009
Table 40: Dermatology Therapeutics Market, Japan, Diseased Population, 2009-2016
Table 41: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2001-2009
Table 42: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2009-2016
Table 43: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2001-2009
Table 44: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2009-2016
Table 45: Dermatology Therapeutics Market, Japan, Prescription Population, 2001-2009
Table 46: Dermatology Therapeutics Market, Japan, Prescription Population, 2009-2016
Table 47: Dermatology Therapeutics Market, Japan, Usage Patterns, 2001-2009
Table 48: Dermatology Therapeutics Market, Japan, Usage Patterns, 2009-2016
Table 49: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 50: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 51: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2009
Table 52: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($) 2009-2016
Table 53: Psoriasis Therapeutics Market, Global, Diseased Population, 2001-2009
Table 54: Psoriasis Therapeutics Market, Global, Diseased Population, 2009-2016
Table 55: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2001-2009
Table 56: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
Table 57: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2001-2009
Table 58: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2009-2016
Table 59: Psoriasis Therapeutics Market, Global, Prescription Population, 2001-2009
Table 60: Psoriasis Therapeutics Market, Global, Prescription Population, 2009-2016
Table 61: Psoriasis Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 62: Psoriasis Therapeutics Market, Global, Usage Patterns, 2009-2016
Table 63: Psoriasis Therapeutics – Phase III Clinical Pipeline, 2009
Table 64: Psoriasis Therapeutics – Phase II Clinical Pipeline, 2009
Table 65: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 66: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 67: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2001-2009
Table 68: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2009-2016
Table 69: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2001-2009
Table 70: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2009-2016
Table 71: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2009
Table 72: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
Table 73: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2001-2009
Table 74: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2009-2016
Table 75: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2001-2009
Table 76: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2009-2016
Table 77: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 78: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2009-2016
Table 79: Atopic Dermatitis Therapeutics – Phase III Clinical Pipeline, 2010
Table 80: Atopic Dermatitis Therapeutics – Phase II Clinical Pipeline, 2010
Table 81: Atopic Dermatitis Therapeutics – Phase I Clinical Pipeline, 2010
Table 82: Atopic Dermatitis Therapeutics – Pre-Clinical Pipeline, 2010
Table 83: Atopic Dermatitis Therapeutics – Discovery Pipeline, 2010
Table 84: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 85: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 86: Acne Therapeutics Market, Global, Diseased Population, 2001-2009
Table 87: Acne Therapeutics Market, Global, Diseased Population, 2009-2016
Table 88: Acne Therapeutics Market, Global, Treatment Seeking Population, 2001-2009
Table 89: Acne Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
Table 90: Acne Therapeutics Market, Global, Diagnosis Population, 2001-2009
Table 91: Acne Therapeutics Market, Global, Diagnosis Population, 2009-2016
Table 92: Acne Therapeutics Market, Global, Prescription Population, 2001-2009
Table 93: Acne Therapeutics Market, Global, Prescription Population, 2009-2016
Table 94: Acne Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 95: Acne Therapeutics Market, Global, Usage Patterns, 2009-2016
Table 96: Acne Therapeutics Market , Clinical Pipeline , 2009
Table 97: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 98: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 99: Rosacea Therapeutics Market, Global, Average Cost of Therapy, ($) 2001-2009
Table 100: Rosacea Therapeutics Market, Global, Average Cost of Therapy ($), 2009-2016
Table 101: Rosacea Therapeutics Market, Global, Diseased Population, 2001-2009
Table 102: Rosacea Therapeutics Market, Global, Diseased Population, 2009-2016
Table 103: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2001-2009
Table 104: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
Table 105: Rosacea Therapeutics Market, Global, Diagnosis Population, 2001-2009
Table 106: Rosacea Therapeutics Market, Global, Diagnosis Population, 2009-2016
Table 107: Rosacea Therapeutics Market, Global, Prescription Population, 2001-2009
Table 108: Rosacea Therapeutics Market, Global, Prescription Population, 2009-2016
Table 109: Rosacea Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 110: Rosacea Therapeutics Market, Global, Usage Patterns, 2009-2016
Table 111: Rosacea Therapeutics – Clinical Pipeline, 2009
Table 112: Dermatology Therapeutics Market, Global, Market Drivers, 2008
Table 113: Dermatology Therapeutics Market, Global, Market Restraints, 2008
Table 114: Dermatology Therapeutics Market, Global, Phase I Pipeline, 2009
Table 115: Dermatology Therapeutics Market, Global, Phase II Pipeline, 2009
Table 116: Dermatology Therapeutics Market, Global, Phase III Pipeline, 2009
Table 117: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2002-2009
Table 118: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 1998-2009
Table 119: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stages, 1998-2008
Table 120: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stages, 2002-2008
Table 121: Dermatology Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stages, 2001-2009

List of Figures:

Figure 1: Dermatology Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 2: Dermatology Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 3: Dermatology Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 4: Dermatology Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 5: Dermatology Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 6: Dermatology Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 7: Dermatology Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2001-2016
Figure 8: Dermatology Therapeutics Market, The US, Revenue Forecasts ($m), 2001-2016
Figure 9: Dermatology Therapeutics Market, The US, Diseased Population, 2001-2016
Figure 10: Dermatology Therapeutics Market, The U.S, Treatment Seeking Population, 2001-2016
Figure 11: Dermatology Therapeutics Market, The US, Diagnosis Population, 2001-2016
Figure 12: Dermatology Therapeutics Market, The US, Prescription Population, 2001-2016
Figure 13: Dermatology Therapeutics Market, The US, Usage Patterns, 2001-2016
Figure 14: Dermatology Therapeutics Market, Europe, Revenue Forecasts ($m), 2001-2016
Figure 15: Dermatology Therapeutics Market, Europe, Diseased Population, 2001-2016
Figure 16: Dermatology Therapeutics Market, Europe, Treatment Seeking Population, 2001-2016
Figure 17: Dermatology Therapeutics Market, Europe, Diagnosis Population, 2001-2016
Figure 18: Dermatology Therapeutics Market, Europe, Prescription Population, 2001-2016
Figure 19: Dermatology Therapeutics Market, Europe, Usage Patterns, 2001-2016
Figure 20: Dermatology Therapeutics Market, Japan, Revenue Forecasts ($m), 2001-2016
Figure 21: Dermatology Therapeutics Market, Japan, Diseased Population, 2001-2016
Figure 22: Dermatology Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016
Figure 23: Dermatology Therapeutics Market, Japan, Diagnosis Population, 2001-2016
Figure 24: Dermatology Therapeutics Market, Japan, Prescription Population, 2001-2016
Figure 25: Dermatology Therapeutics Market, Japan, Usage Patterns, 2001-2016
Figure 26: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 27: Psoriasis Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2016
Figure 28: Psoriasis Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 29: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 30: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 31: Psoriasis Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 32: Psoriasis Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 33: Atopic Dermatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 34: Atopic Dermatitis Therapeutics Market, Global, Average Cost of Therapy, 2001-2016
Figure 35: Atopic Dermatitis Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 36: Atopic Dermatitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 37: Atopic Dermatitis Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 38: Atopic Dermatitis Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 39: Atopic Dermatitis Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 40: Acne Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 41: Acne Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 42: Acne Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 43: Acne Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 44: Acne Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 45: Acne Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 46: Acne Therapeutics Market, Clinical Pipeline by Phase, 2009
Figure 47: Rosacea Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 48: Rosacea Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2016
Figure 49: Rosacea Therapeutics Market, Global, Diseased Population, 2001-2016
Figure 50: Rosacea Therapeutics Market, Global, Treatment Seeking Population, 2001-2016
Figure 51: Rosacea Therapeutics Market, Global, Diagnosis Population, 2001-2016
Figure 52: Rosacea Therapeutics Market, Global, Prescription Population, 2001-2016
Figure 53: Rosacea Therapeutics Market, Global, Usage Patterns, 2001-2016
Figure 54: Rosacea Therapeutics – Clinical Pipeline by Drug Development Phase, 2009
Figure 55: Dermatology Therapeutics Market, Global, Market Indicators, 2009
Figure 56: Dermatology Therapeutics Market, Global, Key Market Events, 2008-2015
Figure 57: Dermatology Therapeutics Market, Global, Leading Companies, 2009
Figure 58: Dermatology Therapeutics Market, Global, Pipeline by Phase, 2009
Figure 59: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Indication, 2009
Figure 60: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Clinical Trial Phase, 2009
Figure 61: Dermatology Therapeutics Market, Global, Licensing Agreements Split by Geography, 2009
Figure 62: GBI Research Methodology, 2010
Figure 63: GBI Research Market Forecasting Methodology, 2010

“The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues” provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Psoriasis is a Strong Growing Market attributed with Increased Competition Coupled with Strong Pipeline

The global dermatology therapeutics market generated approximately $10,039m in 2009. The market is estimated to reach revenues of approximately $12,520m by 2016 growing at a CAGR of 3.2% between 2009 and 2016. In 2010, the market is forecast to reach revenues of about $10,354m. From 2001, the market grew at a CAGR of 2.3% to reach $10,039m in 2009. Psoriasis was one of the fastest growing segments. This growth is primarily attributed to increased competition among the existing products and also a strong pipeline with more emerging therapies. The current market is crowded with biologics and also topical treatments for psoriasis. The pipeline is also very strong with biologics as well as several other treatments for mild to moderate psoriasis. Hence the psoriasis market is expected to reap large revenues with the increased uptake of biologics, and the increased awareness of the disease in patients leading to increased treatment seeking rates at the early stages of the disease.

Increasing R&D in Dermatology Segment Boosts a Strong Clinical Pipeline

In the dermatology sector, most of the companies coordinate their R&D activities to constantly expand their product pipeline with innovative drugs. Though there is a consistent and continuous threat from generics and other alternatives, companies in the dermatology sector are not reluctant to invest in R&D and are focused on offering new products to the market. There are approximately more then 700 drugs in the dermatology pipeline.

-GlaxoSmithKline plc (GSK)
-Johnson & Johnson
-Bayer AG
-Merck & Co., Inc
-Novartis AG
-Sanofi-Aventis
-LEO Pharma A/S
-F. Hoffmann-La Roche Ltd
-L’Oreal
-Galderma S.A
-Nestle S.A.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos